Sanofi, Takeda meds make FDA review list; AZ's nasal vax wins E.U. nod;

 @FiercePharma:  Which specialty drugmakers should Big Pharma buy? Item | Follow @FiercePharma

> The FDA launched early investigations into potential risks of drugs from Sanofi-Aventis, Takeda Pharmaceutical and other companies, the agency said. News

> A shortage of injectable generic drugs for cancer and other serious diseases is putting pressure on hospitals, which are sometimes having to scramble to locate the medicines or search for alternative treatments. Report

> AstraZeneca's nasal flu vaccine has been approved for use in Europe in children aged from 2 up to 18 years and is likely to be available for the 2012/13 influenza season, the drugmaker said. Story

> Astellas Pharma, Japan's second-largest drugmaker, reported a 32 percent decline in nine-month profit because of costs related to its $3.54 billion takeover of OSI Pharmaceuticals. Report

> Eisai, the maker of the world's best-selling drug for Alzheimer's disease, boosted nine-month profit by 25 percent as it increased sales and cut administrative costs. Article

> Novo Nordisk, the world's biggest insulin producer, is expected to announce a 10 billion Danish crown ($1.83 billion) share buyback and new clinical trial data with fourth-quarter results on Wednesday. Item

> Pharmaceutical wholesaler McKesson boosted its full-year earnings forecast range by 10 cents, signaling expectations of a particularly strong fourth quarter. Story

> Big pharma outsourcing will become much bolder in the next 12-18 months as companies attempt to "dramatically attack cost structures," according to the Covance CEO. News

> The Healthcare Businesswomen's Association named Pfizer chief medical officer Freda Lewis-Hall its woman of the year for 2011. Report

Biotech News

@FierceBiotech: Antisoma struggling to survive as another cancer drug flunks Ph3. Report | Follow @FierceBiotech

@JohnCFierce: Reuters says that Sanofi-Genz deal could be wrapped in a week or two. At long last... Story | Follow @JohnCFierce

> Orexigen crashes after FDA demands pre-approval Contrave study. News 

> Roche dumps taspoglutide as analysts read last rites. Item

> Pfizer carving $1.5B from R&D budget, dropping diseases. Story 

Biotech Research News

> U-M study confirms kids can reverse obesity trend. Story 

> Scientists transform skin cell to beating heart cell. Article

> Brits launch $80M push to regenerate heart tissue. Report 

> Memory-enhancing growth factor could treat PTSD. Item 

> Scientists find possible pathway out of nicotine addiction. News 

> Report: stem cell research running into IP brick walls. Article

Manufacturing News

> FedEx ups ante in cold chain game. News

> Platform helps CMOs, clients track and trace. Story

> Baxter CEO ponders FDA warning. Report 

> Seeking middle ground for the FDA. Item 

> Statistics star in validation guidance update. Article 

> Bayer's Babe seeks U.S. manufacturing policy. News

And Finally... Aerobic exercise keeps the aging brain--as well as the aging body--in fighting form, researchers found. Report

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.